Market Place
Sourcing Support
60 Degrees Pharma Expands Tafenoquine Clinical Trial for Babesiosis
11 Dec 2024 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
14 Nov 2024 //
GLOBENEWSWIRE
60 Degrees Pharma Plans Arakoda® Pilot Before US Launch Expansion
03 Oct 2024 //
GLOBENEWSWIRE
60 Degrees Pharma Closes $4M Private Placement At-Market Under Nasdaq
06 Sep 2024 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Announces $4M Private Placement
04 Sep 2024 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Regains Nasdaq Listing Compliance
28 Aug 2024 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
14 Aug 2024 //
GLOBENEWSWIRE
60 Degrees Pharma Supports UK`s SJ733 Study With ARAKODA NDA Access
12 Aug 2024 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
06 Aug 2024 //
GLOBENEWSWIRE
60 Degrees Pharma Gets US Army Contract For ARAKODA Supply Chain
25 Jul 2024 //
GLOBENEWSWIRE
60 Degrees Pharma Signs Agreements For Tafenoquine Babesiosis Trial Sites
19 Jul 2024 //
GLOBENEWSWIRE
60 Degrees Receives FDA Orphan Drug Designation for Tafenoquine
11 Jun 2024 //
GLOBENEWSWIRE
Tafenoquine Trial For Babesiosis To Start At Tufts First Such Study
30 May 2024 //
GLOBENEWSWIRE
60 Degrees Funds Babesia Testing In Chronic Fatigue Patient Samples
20 May 2024 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
15 May 2024 //
GLOBENEWSWIRE
60 Degrees Outlining Tafenoquine Babesiosis Trial Plan
08 May 2024 //
GLOBENEWSWIRE
60 Degrees Receives FDA Comments on Tafenoquine Clinical Trial Protocol
02 May 2024 //
GLOBENEWSWIRE
60 Degrees Pharma to Sponsor Pilot Study of Tafenoquine for Treatment of CB
03 Apr 2024 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use
20 Feb 2024 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
08 Feb 2024 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
31 Jan 2024 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
30 Jan 2024 //
GLOBENEWSWIRE
WallachBeth Capital Announces Pricing of 60 Degrees $2.4 Million Public Offering
30 Jan 2024 //
PR NEWSWIRE
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine
22 Jan 2024 //
GLOBENEWSWIRE
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements
16 Jan 2024 //
GLOBENEWSWIRE
60 Degrees Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine
26 Dec 2023 //
GLOBENEWSWIRE
60 Degrees Pharma Announces Type C Meeting with FDA
15 Nov 2023 //
GLOBENEWSWIRE
60 Degrees Pharma to Present Review of Safety Data of 8-Aminoquinolines
19 Oct 2023 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19
12 Oct 2023 //
GLOBENEWSWIRE
60 Degrees Pharma withdraws mid-stage study application for COVID drug
18 Sep 2023 //
REUTERS
60 Degrees Pharma to Participate in H.C. Wainwright 25th Annual Conference
06 Sep 2023 //
GLOBENEWSWIRE
Genetic Technologies & 60 Degrees Interviews to Air on the RedChip Money Report
01 Sep 2023 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine
22 Aug 2023 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine
15 Aug 2023 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine
31 Jul 2023 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering
14 Jul 2023 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering
12 Jul 2023 //
GLOBENEWSWIRE
Positive PII Data for ARAKODA in Patients with Mild-Moderate COVID-19 Disease
21 Jun 2022 //
PRNEWSWIRE
Data Safety Monitoring Board Recommends Completion of Phase II Study of ARAKODA®
12 Oct 2021 //
PRNEWSWIRE
